Regulatory T (T reg ) cells are essential for self-tolerance and immune homeostasis. Transcription factor Foxp3, a positive regulator of T reg cell differentiation, has been studied to some extent. Signal transducer and activator of transcription factor 3 (STAT3) is known to negatively regulate Foxp3. It is not clear how STAT3 is regulated during T reg differentiation. We show that SMAR1, a known transcription factor and tumor suppressor, is directly involved in maintaining T reg cell fate decision. T-cell-specific conditional knockdown of SMAR1 exhibits increased susceptibility towards inflammatory disorders, such as colitis. The suppressive function of T reg cells is compromised in the absence of SMAR1 leading to increased T helper type 17 (Th17) differentiation and inflammation. Compared with wild-type, the SMAR1 À / À T reg cells showed increased susceptibility of inflammatory bowel disease in Rag1 À / À mice, indicating the role of SMAR1 in compromising T reg cell differentiation resulting in severe colitis. We show that SMAR1 negatively regulate STAT3 expression favoring Foxp3 expression and T reg cell differentiation. SMAR1 binds to the MAR element of STAT3 promoter, present adjacent to interleukin-6 response elements. Thus Foxp3, a major driver of T reg cell differentiation, is regulated by SMAR1 via STAT3 and a fine-tune balance between T reg and Th17 phenotype is maintained.
INTRODUCTION
Disruption of immune suppression contributes to progression of autoimmune diseases. Regulatory T (T reg ) cells are essential for maintenance of immune homeostasis and organization of controlled immune responses. 1 Dysregulated function of T reg cells could account for various immune disorders. In particular, it limits the magnitude of effector responses leading to failure to adequately control infection and inflammation. 2 T reg cells also subside inflammation due to microbial immune responses, including commensals. 3 Upon activation, naive CD4 þ T cells differentiate into different lineages of helper T (Th) cells that are characterized by distinct developmental regulation and biological functions. 4 Activation of naive T cells with immunoregulatory cytokine transforming growth factor (TGF)-b and pleotropic cytokine interleukin (IL)-2 in the absence of IL-6 induces a distinct transcriptional factor Foxp3, which dictates the cell toward induced T reg (iT reg ) cells. 5, 6 It suggests that signaling molecules and transcription factors downstream of TGF-b and IL-2 receptor must work together to induce T reg differentiation. TGF-b alone can generate Foxp3 þ T reg cells both in vitro and in vivo, and in the presence of IL-2, a potent inhibition of TGF-b-driven Th17 cells is achieved. 7 Moreover, STAT5 activation through IL-2 can restrict retinoic acid-related orphan receptor gt (RORgt), which is a transcriptional factor specific for Th17 lineage commitment. 8 Th17 cells are one of the T-cell subtypes that secretes proinflammatory cytokine IL-17; it drives intraepithelial lymphocyte (IEL) accumulation and promotes Th1 response that enhances the inflammatory cascade. 9 Th17 differentiation mostly necessitates the requirement of inflammatory cytokine IL-6, IL-23, and immunoregulatory cytokine TGF-b. 10 STAT3 is a downstream signaling molecule that get activated by IL-6 and IL-23, which in turn transactivate RORgt. STAT3 and RORgt are also reported to bind to IL-17 promoter and activate its gene transcription. [11] [12] [13] Moreover, it was reported that the STAT3 signaling pathway negatively regulates CD4 þ CD25 þ Foxp3 þ T reg cells during the development of anti-inflammatory responses.
14-16 STAT3 binds to CNS2 region of Foxp3 promoter and maintains its expression. 17, 18 Thus Foxp3 gene transcription is under the tight control of specific cooperative external stimuli, contributed by positive regulators such as TGF-b and IL-2 and negative regulators such as IL-6 and IL-23.
Thus T-cell polarization to different lineage commitment depends mostly on the induction of the genes for transcriptional factors and cytokines specific to particular cell type. This requires the coordination of nuclear matrix proteins at the chromatin level with the specific arrangement of chromatin domains distinct to the cell. Nuclear matrix proteins are integral part of the nucleus that has crucial roles in the maintenance and stability of chromatin conformation necessary for the functionality of a particular cell. 20, 21 Such arrangement is facilitated by the anchorage of specific sequences of the DNA to the nuclear matrix. MARs (matrix-associated regions) are known to provide binding sites for specific proteins (MAR-binding proteins or MARBPs) that can influence the transcription of associated gene loci. 22 Different modalities of this complex interaction can dictate the conformation of chromatin loop and thus the repression of a gene in the loci. 23, 24 SMAR1 (scaffold/matrix attachment region binding protein 1), is one such nuclear matrix-associated protein that was initially isolated from the thymocyte library and was shown to be highly expressed in the double-positive T cells where it interacts with the MARb sequence, located 400 bp upstream of the T-cell receptor b (TCRb) enhancer and is highly expressed during the double-positive stage of thymocyte development. 25 SMAR1 causes chromatin remodeling through the recruitment of histone deacetylases (HDACs) and de-acetylation of histones. 24 These chromatin modifications favor the formation of repressor complex in the loci and thus suppress the gene transcription. 26, 27 SMAR1 shares significant homology with other MARBPs such as Cux/CDP, Bright, and SATB1 in the MAR-binding domains. Among them, SATB1 is T lineageenriched chromatin organizer and regulates T-cell differentiation. 28 SMAR1 was identified as an immuno-modulator, and its role in immune responses was studied in detail. SMAR1 transgenic mice were developed, and it showed significant perturbation in the immune responses. 29 Thus studying the chromatin changes during the differentiation of CD4 þ T cells to their effector and regulatory phenotype by SMAR1 has relevance in understanding the molecular events that drive Foxp3 gene expression and stabilize T reg cell phenotype.
To elucidate the role of SMAR1 in regulation of T reg phenotype, we used Foxp3-expressing T reg cells from SMAR1 F/F / Lck-Cre mice (T-cell-specific conditional knockout mice, represented as SMAR1 À / À ) and found that SMAR1 deletion in T reg cells lead to higher susceptibility toward inflammatory disorders. Adoptive transfer of SMAR1 À / À T reg cells does not protect the colitis development in Rag1 À / À mice. It exhibits compromised immune-suppressive function and homeostasis; establishing the role of SMAR1 in maintaining the T reg cell function. Perturbation of SMAR1 in T cells blocked the TGFb1-induced generation of Foxp3 þ T reg cells, and it promotes differentiation of Th17 cells in vitro and in vivo. SMAR1 has a pivotal role in maintaining STAT3 expression; it binds to the regulatory region of STAT3 promoter, which in turn favors Foxp3 expression leading to T reg cell differentiation. This study reveals a critical role of SMAR1 in maintaining the fine-tune balance between T reg and Th17 cell function, and it gives a novel insight into the immune-regulatory mechanisms.
RESULTS

SMAR1
À / À mice are highly susceptible to acute dextran sodium sulfate (DSS)-induced colitis Using mouse model, we have shown that overexpression of SMAR1 perturbs both CD4 þ and CD8 þ T-cell differentiation. Additionally, these mice exhibited dysregulated V(D)J recombination associated with differential regulation of Vb-specific T cells. 29 It is known that CD4 þ T effector lymphocytes have an important role during intestinal homeostasis. 30, 31 With this in mind, we have generated Lck-Cre-driven T-cell-specific SMAR1 knockout mice. To confirm whether SMAR1 may have an influence on effector T-cell phenotype, we checked the SMAR1 À / À CD4 þ T lymphocytes and found that these lymphocytes are effector phenotype (CD62L low CD44 hi ) in nature (Supplementary Figure S1a online) . Further, we checked steady-state absolute number of T-cell (CD4 þ and CD8 þ ) count from the thymus, spleen and mesenteric lymph node from age-and gender-matched adult unmanipulated wild-type (WT) and SMAR1
À / À mice and found that SMAR1 À / À mice is not lymphopenic in nature (Supplementary Figure S1b ). In order to evaluate the role of adaptive immunity on CD4 þ T effector phenotype in intestinal homeostasis, we used SMAR1 À / À and WT mice as experimental model of intestinal inflammation. DSS (3%) was administered through drinking water and monitored for disease progression. SMAR1 À / À mice were more pronounced to DSS-induced colitis as compared with WT mice. The severity of progression of colitis was further judged by body weight loss, diarrhea, and rectal bleeding. Although there was progressive body weight loss in both WT and SMAR1 À / À mice, it was even more severe in SMAR1 À / À mice. After 7 day of DSS treatment, the weight loss of SMAR1 À / À mice was 25 ± 5% while the loss of body weight was about 5% for WT mice (Figure 1a) . By day 7, SMAR1 À / À mice showed severe diarrhea associated with rectal bleeding. Although SMAR1 À / À mice showed colitis score of 10.5±1.5, for WT it was 3.5±0.5 (Figure 1b) , indicating severity of disease progression upon reduced expression of SMAR1. Additionally, gross examination of colon showed features of severe colitis more pronounced in SMAR1 À / À mice that includes atrophied, thinwalled, swollen, opaque proximal colon associated with severe bleeding and stool inconsistency. Both cecum and colon size were significantly shorter and quantified by measuring organ weights, which were notably less in SMAR1 À / À mice ( Figure 1c) . The disease activity index based on rectal bleeding, stool consistency, and detection of blood in stool was significantly higher (P-value o0.001) in SMAR1 À / À mice than in WT mice at day 7 of DSS treatment (Supplementary Figure S1c) . Macroscopic evidence of colonic damage was not observed in the SMAR1 À / À mice without DSS challenge. Colonic damage, especially effect in the transverse and descending segments of colon, increase in the ratio of colon length to weight, shortening of the colon, was examined only in mice with DSS treatment. In this report, compared with DSStreated WT mice, SMAR1 À / À mice had considerably shorter colon and elevated ratio of colon length to weight (Figure 1d) . The level of colonic injury characterized by epithelial loss, crypt damage, ulceration, and inflammatory cell infiltration was considerably higher in SMAR1 À / À mice ( Figure 1e ). DSS untreated SMAR1
À / À mice did not show any inflammatory bowel disease symptoms that includes massive infiltrations of inflammatory leukocytes, loss of goblet cells as well as colonic inflammation. We then checked the levels of proinflammatory cytokine taking cells from colonic lamina propria (LP). We observed higher secretion of proinflammatory cytokine such as interferon (IFN)-g, IL-17 and tumor necrosis factor (TNF)-a in SMAR1
À / À mice. There was no apparent change in the level of IL-4 indicating that Th2 pathway remains unaltered (Figure 1f-i) . In addition to increased colonic inflammation, SMAR1
À / À mice showed more immunoglobulin A (IgA) in the circulation compared with WT mice (Supplementary Figure S1d) . The colonic LP and IELs of SMAR1 À / À mice had less CD4 þ Foxp3 þ T reg cells than WT mice (Figure 1j,k) .
þ IELs of SMAR1 À / À mice also had more proinflammatory Th1 and Th17 cells (Supplementary Figure S1e) . Nevertheless, the overall ratio of Th17 cells to Foxp3 þ T reg cells was significantly higher in SMAR1 À / À mice À / À mice treated with DSS. Data represent mean±s.e.m. of n ¼ 6 mice/genotype. P-value were calculated with Student's t-test; **Po0.002 (mice are taken from same breed and co-caged). (b) Stool consistency and rectal bleeding were monitored at seventh day of DSS administration, and colitis was scored for each mouse. Colitis was graded on a scale of 0-12 as described in the Methods. Data represent the mean ± s.e.m. P-value were calculated with Student's t-test; **Po0.001. (c) Colon weight of DSS-treated mice was measured on day 7. Data represent the mean±s.e.m. P-values were calculated with Student's t-test; **Po0.006. Figure 2b) . Interestingly, in the course of colonic inflammation, there was 3.5-4.5-fold higher numbers of Ki67 (Figure 2c ). Thus SMAR1 À / À mice showed increased effector T-cell activation along with lower number of T reg cell population. We presumed that in SMAR1 À / À mice decreased Foxp3 expression might contribute to generation of increased proinflammatory responses. To prove this, we treated mice with 3% DSS for 5 days and left it to recover using normal water as detailed in Methods. SMAR1
À / À mice were highly susceptible to this treatment by day 14 and showed disease symptoms as described before. In contrast, WT mice survived over this time course and maintained their body weight while the body weight of SMAR1 À / À mice decreased gradually by 15-20% at day 5 and lost 425% of their initial body weight at day 14 ( Figure 2d ). SMAR1 À / À mice developed rectal bleeding and diarrhea early on day 7 and showed severe symptoms of colitis (colitis score 10 ± 2) and showed no improvement from day 6 to day 14. However, severe diarrhea À / À mice progressively decreased and had lost 46% of their initial T reg cells at day 14. In contrast, the frequency and total number of Foxp3 þ T reg cells in WT mice was gradually restored at day 14 ( Figure 2f ). The recovery of T reg cells in WT mice was mainly due to expansion of T reg population ( Figure 2g ). These results indicate that SMAR1 might be involved in stabilizing as well as maintaining Foxp3 þ T reg response during acute intestinal inflammation.
À / À mice showed upregulation of the gut-homing markers in T cells
To find the cause of increase CD4
þ T-cell accumulation in the colon of SMAR1
À / À mice, we checked the level of gut-homing markers during development of acute colitis. In addition to CD44 (Supplementary Figure S2a) , both integrin C-C motif chemokine receptor 9 (CCR9) and a4b7 in the colon LP and IELs were increased substantially to 2-3.5-fold in SMAR1 À / À mice compared with WT mice (Figure 3a) . Our data indicate that the increased accumulation of CD4 þ T cells in SMAR1 À / À mice is due to dysregulated expression of gut-homing markers. The proinflammatory Th1 and Th17 cytokines have a major impact on inflammatory bowel disease progression. 31 We therefore checked the levels of proinflammatory cytokines in colonic T cells during disease progression. Noticeable increase in the Th1 and Th17 cytokine-producing cells in the colon of DSS-treated SMAR1 À / À mice were observed (Figure 3b ). At the same time, 5-6-fold increase in proinflammatory and inflammatory cytokines from total colonic LP cells from SMAR1 À / À mice was observed ( Figure 3c ). Additionally, the SMAR1 À / À mice shows increased IEL, LP, and mesenteric lymph node CD4 þ CD8 þ cell population and 3 ± 1-fold increased number of CD4 þ and total IEL as well as CD4 þ and total LP cells ( Figure 3d ,e) in addition to CD19 þ Figure S2b) compared with WT mice. Hematoxylin and eosin staining of the diseased colon samples showed some of the polymorphonuclear leukocytes. The flow cytometry data showed that there was also major increase in the dendritic cell and neutrophil populations in the colon, both in colonic LP and IEL compartment ( Figure 3f ). All these observations clearly reveal that there was accumulation of CD4 þ T lymphocytes and production of proinflammatory cytokines in the colonic LP in addition to neutrophils and dendritic cells, which collectively contribute to disease progression.
B-cell population (Supplementary
SMAR1-deficient T reg cells showed altered suppressive activity in vitro
Transcription factors are important for directing the differentiation of proinflammatory Th1 and Th17 cells. Some of them were recently shown to have unique and essential roles in controlling Foxp3
þ T reg cell function. 32, 33 The polarization of naive CD4
þ T cells toward Th1 and Th17 cells showed 4-5-fold downregulation of SMAR1 (Supplementary Figure S3a) ; therefore, to assess the involvement of SMAR1 in generation and function of T reg cells, SMAR1 expression was checked in purified CD4
þ CD25 þ T reg cells and CD4 þ CD25 À non-T reg cells isolated from WT mice. T reg cells expresses high level of SMAR1 compared with non-T reg cells (Figure 4a) . iT reg cells and in vitro activated nT reg cells also showed high level of SMAR1 expression (Figure 4b ). SMAR1 expression in nT reg was further confirmed by mRNA expression from both in vitro activated CD4
þ T cells as well as nT reg . The results showed that in vitro activated nT reg expresses equivalent level of SMAR1 compared with in vitro activated CD4 þ T cells ( Figure 4c ). Addition of IL-2 alone was sufficient to induce SMAR1 expression in T reg , upon TCR stimulation (Supplementary Figure S3b,c) . Confocal imaging of in vitro generated iT reg and in vitro activated nT reg showed drastic increase in SMAD 1/2/3 expression and translocation of SMAD 1/2/3 to nucleus, demonstrating that SMAD 1/2/3 is only activated under T regpolarizing condition. It is also found that SMAR1 is expressed more in T reg -inducing conditions compared with unstimulated control cells (Figure 4d ), suggesting the strong possibility of epigenetic control of SMAR1 during T reg lineage commitment. Furthermore, we looked into what functions of T reg cells were altered by SMAR1 deletion. The number of conventional T cells expressing integrin a4b7 and CCR9 were found to be more in SMAR1
À / À mice. This clearly suggests that the suppressive activity of T reg cell over conventional T cell is altered in the absence of SMAR1. Elevated levels of conventional CD4 þ T cell produce high amount of proinflammatory cytokines in the colon leading to inflammation, even though T reg cells are present in the colon. To address this issue, we directly evaluated the immune-suppressive activity of SMAR1-deficient T reg cells; we used an in vitro suppression assay and observed that SMAR1-deficient T reg cells showed reduced suppressive activity and were unable to control proliferation of coexisting effector CD4 þ T cells with the similar efficiency as WT T reg cells (Figure 4e) . Moreover, this was not due to a major deficiency in their maintenance in vitro (Supplementary Figure S3d ). Therefore, SMAR1 is important to maintain intact immune-suppressive function of T reg cells in vitro.
SMAR1 is essential for TGF-b1-induced Foxp3 expression in T reg cells
We assessed whether in the absence of SMAR1 the generation of Foxp3 þ T reg cells is altered. Naive CD4 þ CD62L hi CD25 À T lymphocytes were cultured in the presence of anti-CD3 and anti-CD28 along with TGF-b1 to polarize cells toward induced Foxp3 þ T reg cells. Compared with WT, SMAR1 À / À CD4 þ T cells expressed about 3-4-fold reduced both Foxp3 mRNA and protein expression. (Figure 5a-c) . The similar experiment was carried out by using different concentration of TGF-b1 (5, 10, 20 ng ml
). Fluorescence-activated cell sorter (FACS) analysis showed 2.5-3.5-fold decreased Foxp3 expression in 
SMAR1
À / À CD4 þ T cells (Figure 5d ). Further treatment with TGF-b1 along with either IL-2 or retinoic acid (RA) did not significantly alter the pattern, indicating that the major effect in the change of Foxp3 expression is primarily due to TGF-b1 ( Figure 5a ). We could not also detect any significant changes in the phosphorylation of SMAD2/3 that are the targets of Figure S4a) . Thus, for the generation of Foxp3 þ T reg cells, it is possible that SMAR1 has a role downstream of SMAD2/3. Several groups have reported the role of transcription factors in the regulation of balance between T reg and Th17 cells during inflammation. We therefore checked whether SMAR1 is (Figure 5h-j) . Addition of IL-6 provides considerable enhancement (Figure 5h-j) . However, TGF-b1 alone did not perturb the Th17 polarization of SMAR1 À / À CD4 þ T cells, because Foxp3 expression has not been restored. Therefore, SMAR1-deficient CD4 þ T cells are more prone to express Th17 cell cytokines.
cells (Supplementary
SMAR1-deficient TGF-b1-induced T reg cells showed altered levels of cytokine genes expression
We checked the role of SMAR1 on TGF-b1-induced T reg cells. Notably, Foxp3 expression was downregulated along with genes that are important for T reg phenotype. The levels of surface marker CD25 remain unchanged, while CTLA-4, CD103, and Icos were decreased in SMAR1-deficient T reg cells (Supplementary Figure S5a) . The result indicates SMAR1-deficient T reg cells have reduced suppressive function. Moreover, it has also been found that an IL-10 mRNA level was reduced by fourfold ( Figure 6a ). IL-10 is a well-known anti-inflammatory cytokine and has a significant role in T regsuppressive function, especially in colitis. IL-10 À / À mice develop spontaneous inflammation of the colon. 34, 35 Not only mRNA level of IL-10 were downregulated in SMAR1-deficient T reg cells but notably the protein level were also reduced ( Figure 6b ). In addition, several effector Th1 and Th17 cell cytokines, including IL-17, IFN-g, and TNF-a, were found to be upregulated (Figure 6b) . Also Foxp3 þ T reg cells from 
SMAR1
À / À mice showed no difference in the level of NK1.1 compared with WT T reg cells (Supplementary Figure S5b) .
IL-10-producing CD4
þ T reg cells are also essential to control immune responses during DSS-induced colitis. 36 To investigate the role of IL-10 in colitis condition of SMAR1 À / À mice, we checked IL-10 production. We found that the level of IL-10 in CD4 þ T cells were less in SMAR1 À / À mice compared with WT mice (Figure 6c) . Moreover, there was 3.5-fold decrease in total colonic IL-10 level in SMAR1 À / À mice as compared with WT mice (Figure 6d,e) . These data collectively reveal that SMAR1-deficient T reg cells expressed altered levels of several effector cytokine genes and reduced level of IL-10, which are essential for its suppressive activity. It suggests that SMAR1 controls the expression of proinflammatory cytokine genes and maintain effector function of T reg cell lineage commitment.
SMAR1-deficient T reg cells do not protect colitis
To evaluate whether deficiency of SMAR1 could have functional consequences on the capacity of T reg to control colitis, we used a well-known depicted model of T-cell transfer colitis. Colitogenic CD4 þ CD45RB hi CD25 À T lymphocytes were adoptively transferred into Rag1 À / À mice either alone or along with WT T reg and SMAR1 À / À T reg . As anticipated, colitogenic T lymphocytes initiate severe colonic inflammation coupled with considerable weight loss, which was suppressed when WT T reg were co-transferred (Figure 7a) . On the contrary, SMAR1 À / À T reg when co-transferred with colitogenic T lymphocytes failed to suppress inflammation and weight loss (Figure 7a) . Consistently, mice co-transferred with SMAR1
À / À T reg showed augmented colonic inflammation associated with major infiltration of inflammatory cells as compared with mice co-transferred with WT T reg (Figure 7b-d) . The Rag1 À / À mice co-transferred with SMAR1 À / À T reg cells fail to control inflammation due to downregulation of Foxp3 expression and elevated production of proinflammatory cytokine IL-17 compared with mice co-transferred with WT T reg cells (Figure 7e,f) 
cells, when injected into Rag1
À / À mice together with WT T reg cells, showed prevention of colonic inflammation (Figure 7g,h ). Hematoxylin and eosin staining showed normal structure of the colon, with typical crypts containing profused goblet cells, and some negligible infiltrates (Figure 7i,j) . Flow cytometric analysis confirmed noticeable decrease in the percentage of CD4 þ T lymphocytes infiltrating the colon, in addition to CD4 þ T lymphocytes producing IFN-g, TNF-a, and IL-17 ( Figure 7k) . Collectively, these data suggest that SMAR1 control behavior of T reg cells in colonic inflammatory milieu. Control of disease consequently with WT T reg cell was caused by maintenance of suppressive function and stability of Foxp3 expression in the presence of SMAR1 (Figure 7l) . These results reveal that provision of WT T reg cells along with SMAR1-deficient CD4 þ CD45RB hi CD25 À T cells prohibited inflammatory bowel disease, and alteration in SMAR1-deficient T reg cells are especially the cause of inflammatory bowel disease.
SMAR1 control STAT3 expression in Foxp3
þ T reg cells
We further explored the mechanism responsible for altered suppressor activity of SMAR1-deficient T reg cells. In our initial study, we observed a lesser amount of Foxp3 mRNA as well as protein expression in SMAR1-deficient T reg cells compared with WT T reg cells. Furthermore, we observed that, during the course of DSS-induced colitis in WT scenario, the expression of SMAR1 in colonic CD4 þ T cells was drastically downregulated and inversely the expression of STAT3 is upregulated, which leads to generation of more proinflammatory Th17 cells (Supplementary Figure S6a,b) . As we have shown previously, after deletion of SMAR1 in T cells, the number of Th17 cells goes high in colonic LP and 2.5-fold higher STAT3 level in CD4
þ T cells at the seventh day of DSS treatment (Supplementary Figure S6c) , hence an altered Foxp3 expression was observed. In order to rule out the possibility that TCR signaling is not a cause of the observed altered Foxp3 expression, we checked the level of TCRb and CD69 on the surface of CD4 þ T lymphocytes. CD69 is the early activation marker and usually upregulated upon TCR stimulation. The data showed no major difference in TCRb (Supplementary Figure S6d) and CD69 (Supplementary Figure S6e) (Figures 5j and 8a) . TGF-b1 stimulation particularly eliminates IL-17 production in WT CD4 þ T cells. As SMAR1
À / À CD4 þ T cells fail to suppress IL-17 production upon TGF-b1 treatment, it indicates that Foxp3 was unable to inhibit IL-17 expression. Higher IL-17 production in SMAR1
þ T cells was possibly due to high level of pSTAT3 in these T cells after TGF-b1 treatment (Supplementary Figure S6f;  Figure 8a ). Thus we speculate SMAR1 controls STAT3 expression, which in turn regulates Foxp3 production in CD4 þ T cells. Next we examined the effect of SMAR1 deficiency on the binding of STAT3 in Foxp3 promoter. SMAR1
þ T cells showed higher IL-17 expression and that was probably due to upregulation of STAT3 upon TGF-b1 treatment (Figures 5h and 8b) . As mentioned above, STAT3 binds directly to Foxp3 promoter and act as a repressor for its transcription. CD4
þ T cells treated with TGF-b1 inhibit the STAT3 expression and resulted in less binding of STAT3 to the Foxp3 promoter in WT CD4 þ T cells (Figure 8c ). Because of elevated STAT3 level in SMAR1
À / À CD4 þ T cells, (Figure 8b ) more binding of STAT3 to Foxp3 promoter was observed after TGF-b1 plus IL-6 treatment compared with WT CD4 þ T cells (Figure 8c ). On the other hand, treatment with only TGF-b1 was not able to reduce the binding of STAT3 to Foxp3 promoter in SMAR1
À / À CD4 þ T cells (Figure 8c ). These results showed that TGF-b1 is not able to elevate Foxp3 expression owing to upregulation of STAT3, which represses Foxp3 transcription in SMAR1
À / À CD4 þ T cells. As SMAR1 is an MARBP and as these proteins have the propensity to bind at AT-rich sequences, which frequently flank different promoters, we analyzed the promoter sequence of STAT3-inducible gene. Computational analysis using MARFINDER program predicted potential MARs in the STAT3 promoter within B400 bp upstream of IL-6 response element and B300 bp upstream of transcription start site (TSS; Supplementary Figure S6g) . We assessed whether SMAR1 binds to these MAR regions in STAT3 gene promoter. We treated naive CD4 þ T cells from the spleen of WT mice using TGF-b1 plus IL-2 along with TCR-specific stimulation and analyzed whether it could influence the binding of SMAR1 to STAT3 promoter during generation of iT reg . We processed iT reg cells for chromatin immunoprecipitation coupled quantitative PCR to assess the binding of SMAR1 to STAT3 promoter. We precisely investigated the promoter and IL-6 response elements, which are known to have an important role in activation of STAT3 gene expression. [37] [38] [39] [40] We found that SMAR1 strongly binds to MAR region within the IL-6 response elements of STAT3 gene. The potential binding sites of SMAR1 at positions À 660 to À 840 and À 229 to À 478, belonging to IL-6 response elements were found in the proximal region of the promoter (Figure 8d; Supplementary Figure S6g) . To further verify this, SMAR1-binding site were deleted between À 321 to À 337 from the TSS in a construct containing STAT3 promoter upstream of luciferase. The deleted region contains a strong MAR site, and it belongs to IL-6 response element where SMAR1 binds. The deletion considerably increases the reporter activity in response to IL-6 activation ( Figure 8e ) and it suggests that this site is important for STAT3 promoter activity. Next, we checked the binding of SMAR1 to STAT3 promoter in CD4 þ T cells, treated with anti-CD3 and anti-CD28 alone or with anti-CD3 anti-CD28 along with TGF-b1 plus IL-2 and found that TGF-b1 plus IL-2 treatment considerably enhanced the binding of SMAR1 to the promoter compared with the control condition (Figure 8f ). In addition, the enrichment of SMAR1 to STAT3 promoter in CD4 þ CD25 þ T reg cells from the spleen of WT mice is relatively high compared with the CD4 þ CD25 À T cells (Figure 8g ). The binding of SMAR1 to STAT3 promoter in Foxp3 þ T reg cells is directly correlated with the transcriptional repression of gene evidenced by the enrichment of HDAC1 and positive epigenetic modifications, including H3K9 acetylation (Figure 8d,f,g ). However, TGF-b1 and IL-2 treatment enhanced the binding of SMAD2/3 to the Foxp3 promoter in WT as well as SMAR1 Figure S6h) . Our data showed that SMAR1 binds to the transcriptional regulatory regions of STAT3 and modulates its expression, which in turn governs the Foxp3 expression upon TGF-b1 and IL-2 treatment and maintains the T reg phenotype, whereas these events were defective in SMAR1 À / À T cells, leading to the generation of proinflammatory T cells. These results demonstrated a pivotal role of SMAR1 in the generation of Foxp3 þ T reg cells.
DISCUSSION
Effector CD4 þ T cells are responsible for the production of the proinflammatory cytokines that causes tissue damage. T reg cells are responsible for maintaining peripheral tolerance of effector T cells and keeping these cells in check. 3 In this study, we showed for the first time the role of a MARBP SMAR1 in maintaining the balance between Th17 and T reg cells and its role in inflammatory diseases. Our results demonstrate that, in the absence of SMAR1, T reg cells lose their suppressive activity that leads to increased production of proinflammatory cytokineproducing T cells in the colon, which showed upregulation of gut-homing markers integrin a4b7 and CCR9 that helps to accumulate in the gut during colonic inflammation. This study revealed an indispensible role of SMAR1 in regulating T reg cell function and immune tolerance and maintaining the balance between T reg cells and Th17 cells.
Deletion of SMAR1 in T cells enhances Th17 cells in DSSinduced colitis. This preferential increase of Th17 cells were not limited to DSS-induced colitis; it has also been observed in T-cell transfer model of colitis and in vitro from TGF-b1-treated naive CD4 þ T cells. Collectively, these observations point toward the fact that the differentiation of Th17 cells is favored during the absence of SMAR1 and increased level of Th17 cells is the reason for disease progression. It can also be inferred here that T reg cells are not able to gain control on Th17 cell proliferation. Transfer of T reg cells along with CD4 þ CD45RB hi T cells from SMAR1 À / À mice into syngeneic Rag1 À / À mice was not able to prevent the disease, although We found that CD25, CTLA-4, Icos, and CD103 surface levels were either equivalent or elevated in SMAR1-deficient T reg cells, suggesting that suppressive function of T reg cell is severely compromised. SMAR1-deficient T reg have no defect in proliferation as shown in in vitro proliferation assay (Supplementary Figure S3d) . This eliminates the possibility that SMAR1 has no role in T reg cell proliferation, rather it has a crucial role in suppressive function of T reg cells. However, SMAR1-deficient T reg cells showed reduced levels of IL-10 and showed upregulation of proinflammatory gene expression, including TNF-a, IL-17, and IFN-g. Studies have shown that IL-10-deficient mice lack T reg cells and are capable of controlling inflammatory responses in the intestine. 39, 41 That led us to argue reduced suppressive function of SMAR1-deficient T reg cells. We have demonstrated that SMAR1-deficient T reg cells showed enhanced ability to produce inflammatory cytokines, indicating that SMAR1 downregulation under inflammatory condition could allow T reg cell to acquire effector function that contribute to inflammation. Our study therefore suggests that SMAR1 expression in T reg cells is important for the modulation of T reg cell function and immune response. Considering above observations, it is clear that SMAR1 is having a crucial role in suppressive function of T reg cells. Because of the absence of SMAR1, T reg cells fail to suppress the reactive CD4 þ T cells, resulting in severe damage of the whole balance among CD4 þ T cells and consequent development of the disease. CD4 þ regulatory T cells have an essential role in intestinal homeostasis. T reg cells are characterized by constitutively higher level of transcription factor Foxp3, 6, 42 which is considered to confer their regulatory activity. T reg cells have the ability to block colitis upon transfer in vivo. We found constitutive expression of SMAR1 in nT reg cells as well as in iT reg cells. Our data also support the idea that IL-2 contributes to the expression of SMAR1 by T reg . Recent reports suggest that the T reg cell required the acquisition of specific transcription factors to exhibit control in defined polarized situation. 43, 44 Previous reports demonstrated that increased expression RORgt in T reg can produce IL-17A
45 that leads to compromised T reg function. We found that, in the colon, the expression of RORgt was influenced by SMAR1 in T reg and increased expression of IL-17A compared with WT. The expression of Foxp3 is reduced by genetic alteration causing upregulation of RORgt, followed by increased level of IL-17A production and generation of effector Th17 cells. 8, 46, 47 We observed high IL-17 expression in SMAR1-deficient T reg cells. We also found that Foxp3 level was also reduced. Therefore, we speculate that the loss of SMAR1 has severe effects on Foxp3 expression, which leads to the loss of Foxp3 and induction of IL-17A conferring a T reg phenotype to Th17 phenotype.
SMAR1 is a member of MARBP family that interacts with regulatory regions (promoters/enhancers) of the gene and potentially controls the transcriptional activity. 25 MAR, also known as Scaffold/matrix attachment regions (S/MARs), are sequences in the DNA of eukaryotic chromosomes where the nuclear matrix attaches. 48, 49 Studies on specific genes lead to the outcome that the dynamic and complex organization of the chromatin mediated by S/MAR elements has an important role in the regulation of gene expression. 50 Therefore, SMAR1 exerts diverse function to control gene expression in a cell type-specific manner. 51 Nevertheless, the understanding of how SMAR1 regulates immune function is far from complete.
Indeed, our studies open a new role of SMAR1 in controlling T reg cell function. The function of T reg cell is dependent on Foxp3 expression. Foxp3 is an important transcription factor that regulates many essential genes that governs the T reg cell development. 42 The predominant T-cell type that expressed Foxp3 was CD4 þ CD25 þ T cells, the same population that has been reported to suppress proliferation and cytokine production in conventional CD4 þ T cells. Foxp3 appears to exert its function through the transcriptional repression of many genes, including that of the effector cytokines. 33 The factors mediating the transactivation or transrepression are critical to delineate the molecular mechanisms involved in controlling regulation of transcription factor Foxp3. Previous reports suggest that TGF-b mediates enrichment of SMAD2/3 at the Foxp3 promoter and the activation of Foxp3 transcription. 52, 53 On the other hand, STAT3 is reported to bind to regulatory (silencer) regions of Foxp3 promoter 15, 53 and suppress its expression.
Deficiency of SMAR1 in T reg cells leads to uncontrolled STAT3 production and, in turn, production of IL-17. Additionally, IL-6-mediated suppression of SMAR1 has a direct effect on the enrichment of STAT3 to the Foxp3 promoter, although inhibition of SMAR1 could restore the STAT3 enrichment in Foxp3 promoter in response to TGF-b1 in SMAR1
À / À CD4 þ T cells. Finally, IL-6 could influence Foxp3 epigenetically by losing the chromatin, allowing more access of STAT3 to the Foxp3 promoter. This data support that overexpression of STAT3 is a key factor in defective Foxp3 induction in SMAR1
À / À CD4 þ T cells. Thus we speculate that SMAR1 controls transcriptional activity of STAT3 and in turn regulates the Foxp3 expression and maintain the T reg cell phenotype. It is now necessary to answer how SMAR1 is regulating the STAT3 expression. It is known from earlier studies that SMAR1 exerts its transcriptional activity mainly through DNA binding. 24, 54 Presence of several MAR-binding region at the promoter of STAT3 makes us believe that SMAR1 can bind to these site and influence the STAT3 expression. SMAR1 bound to regulatory regions of STAT3 locus and inhibits the activity of STAT3, a negative regulator for Foxp3. 55, 56 In support, we observed that in Th17 cells SMAR1 expression was very low and it is not able to bind to STAT3 locus. However, in T reg cells, SMAR1 binds at a position À 660 to À 840 associated with strong MAR and À 229 to À 478 associated with IL-6 response elements from the TSS of STAT3 locus. We found that deletion of SMAR1-binding MAR site located at À 321 to À 337 from the TSS in STAT3 promoter attenuated the promoter activity, suggesting that this region is essential. These observations conforms the fact that SMAR1 controlled Foxp3 expression via STAT3 dependent manner and governs the overall balance between Th17 and T reg cells.
Our results showed that in WT scenario treatment with TGF-b1, SMAD2/3 bind to the Foxp3 promoter at the same time SMAR1 bind to STAT3 promoter, which further suggested a positive role for SMAR1 in the transcriptional regulation of STAT3, this activity was regulated through TGF-b signaling. It suggests that SMAR1 is involved in regulating Foxp3 expression in TGF-b1-induced T reg cells, and ultimately it decides the plasticity of T reg cells. Here we found that SMAR1 has an important role in switching on STAT3 and IL-17 in WT CD4 þ T cells, which indicates a function for SMAR1 in inhibiting the binding of STAT3 to the Foxp3 promoter. The inability of CD4 þ T cells lacking SMAR1 to induce Foxp3 resulted in an intrinsic preference for Th17 differentiation. On the basis of data presented here, we propose that SMAR1 induces Foxp3 expression by promoting the binding of SMAD2/3 to the Foxp3 promoter (enhancer) and by removing the negative factor STAT3 to the Foxp3 promoter (silencer).
Further studies are required in order to understand the complex interplay of these transcription factors in the control of T reg adaptation vs. pathogenicity during inflammation. Accumulation of T reg is critical for their ability to maintain tissue homeostasis. A role of SMAR1 in promoting T reg fitness/ survival was revealed under the inflammation or homeostasis proliferative situation. Finally, our results support the idea that the role of SMAR1 in T reg is complex and affects many physiological functions. In the present study, we uncover potential roles; in particular, SMAR1 controls excessive effector polarization by T reg cells to Th17 cells and their suppressive activity during inflammation. Although identification of the factors involved in the stability of T reg is likely to offer important therapeutic interventions, the role of SMAR1 in controlling of T reg fate during inflammation will be equally critical to our understanding of peripheral tolerance and development of safe therapeutic approaches.
METHODS
Mice. T-cell-specific (LCK-Cre/SMAR1 f/f ) conditional knockout mice (SMAR1 À / À ) were generated at Ozgene, Bentley, Australia. Rag1
À / À mice were a gift from S Rath (National Institute of Immunology, New Delhi, India). Mice were maintained under specific pathogen-free conditions in the animal resource facility of National Centre for Cell Science. C57BL/6J and all other mice were inbred in the experimental animal facility of the NCCS, Pune, India. SMAR1 À / À mice were maintained as colony by homozygous Â homozygous (brother Â sister) and the WT mice were C57BL/6J. The weanling of both WT (C57BL/6J) and SMAR1
À / À (LCK-Cre/SMAR1 f/f ) mice were housed together during the course of experiment. Mice were killed between 6 and 8 weeks of age, except for the Rag1 À / À mice, which were killed at 13-15 weeks of age. The experiments were conducted according to protocols approved by the Institutional Animal Ethical Committee of NCCS.
Flow cytometry. Surface and intracellular staining was performed on FcR-blocked lymphocytes using the antibodies listed in Supplementary Material and Methods. For intracellular cytokine determination, up to 1 Â 10 6 lymphocytes per well were stimulated with 50 ng ml À 1 phorbol myristate acetate, 200 ng ml À 1 ionomycin, 10 mg ml À 1 brefeldin, and 2 mM monesin in complete media for 6 h at 37 1C. Cells were first stained with surface markers, followed by fixation in 2% formaldehyde and permeabilization with 0.05% saponin, and later followed by intracellular staining for cytokines with the fluorescence-labeled antibodies listed in Supplementary Material and Methods. Flow cytometry analysis was conducted on an upgraded five-color FACS caliber, FACS canto, or LSR II flow cytometer (BD, San Jose, CA), and data were analyzed using the FACS DIVA software (San Jose, CA). Sorting of CD4 þ CD62L hi CD25 À , CD4 þ CD45RB hi CD25 À , and CD4 þ CD25 þ cells was performed using a FACS area instrument (BD).
Induction of DSS colitis. Experimental colitis was induced by adding DSS (36,000-55,000 kDa, MP Biomedicals (Solon, OH); Cat.: 160110) to the drinking water at concentration of 3% (wt/vol). Animals were treated either for 5 days and then allowed to recover by normal drinking water for additional 9 days or were treated continuously with DSS for 7-11 days. Colon was assessed for weight, length, and histology. The animal were weighed daily and monitored for signs of distress, rectal bleeding, stool consistency, detection of blood in stool, and body weight loss measurement. An individual score was given for each one of this parameter, and disease activity index ranging from 0 to 4 was calculated by combining all the three scores. 57 In order to get the uniform results, mice were taken from the same breed and were cocaged from the time of weaning all throughout the experiment.
Data analysis. Groups were compared with the Prism software (GraphPad, La Jolla, CA) using two-tailed unpaired Student's t-test. Data are presented as mean±s.e.m. Po0.05 was considered significant.
SUPPLEMENTARY MATERIAL is linked to the online version of the paper at http://www.nature.com/mi
